Login
Companies $LAB
$0.60 -$0.11 (15.04%) Live
STANDARD BIOTOOLS INC. logo

STANDARD BIOTOOLS INC.

standardbio.com

What Do They Do?

Sells instruments, consumables and services for mass cytometry, spatial biology and genomic research to academic, clinical research and biopharmaceutical customers.

Who Are Their Customers?

The company sells instruments and consumables to academic and translational research institutions, research and cancer labs, and biopharma and biotech firms through its direct sales force and, in some countries, distributors or sales agents.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 10% from one customer

Do Revenues Turn Into Profits?

No. It lost $74.9M in FY2025.

Operating income, FY2025
−129% of revenue
▲ +14% (Loss) vs FY2024 (−$127.5M, −140%)
Net income, FY2025
−88% of revenue
▲ +46% (Loss) vs FY2024 (−$138.9M, −153%)
Free cash flow, FY2025
−97% of revenue
▲ +46% (Loss) vs FY2024 (−$151.8M, −167%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −1%
vs $19.6M in Q3 FY2025
Net income
▲ Turned profitable
vs −$34.7M in Q3 FY2025
Product revenue share of revenue vs 70.6% in Q3 FY2025
  • Nov 3, 2026 Sold its Microfluidics business to ARCHIMED The business will operate as Biomark Scientific.
  • Sep 30, 2026 Agreed to sell its Mass Cytometry business to Element Closing is subject to stockholder approval, completion of the Treeline merger and other conditions.
  • Aug 5, 2026 Withdrew its full-year 2026 revenue outlook The company cited its pending merger with Treeline Biosciences.
  • Jun 6, 2026 Agreed to an all-stock merger with Treeline Biosciences The combined company was expected to operate as Treeline Biosciences.
Revenue over time
Product revenue Services and other revenue Development revenue Other revenue Service revenue Collaboration and other revenue
$200M$100M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support